Permeability of the blood–brain barrier predicts no evidence of disease activity at 2 years after natalizumab or fingolimod treatment in relapsing–remitting multiple sclerosis

Stig P. Cramer*, Helle J. Simonsen, Aravinthan Varatharaj, Ian Galea, Jette L. Frederiksen, Henrik B.W. Larsson

*Corresponding author for this work
6 Citations (Scopus)
52 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Permeability of the blood–brain barrier predicts no evidence of disease activity at 2 years after natalizumab or fingolimod treatment in relapsing–remitting multiple sclerosis'. Together they form a unique fingerprint.

Medicine & Life Sciences